Lukas E Dow
Overview
Explore the profile of Lukas E Dow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
4835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madorsky Rowdo F, Martini R, Ackermann S, Tang C, Tranquille M, Irizarry A, et al.
Cancer Res
. 2025 Feb;
85(3):551-566.
PMID: 39891928
Precision medicine approaches to cancer treatment aim to exploit genomic alterations that are specific to individual patients to tailor therapeutic strategies. Yet, some targetable genes and pathways are essential for...
2.
Nease L, Church K, Delclaux I, Murakami S, Astorkia M, Zerhouni M, et al.
Nat Cancer
. 2024 Oct;
5(12):1868-1884.
PMID: 39438623
Selenocysteine-containing proteins play a central role in redox homeostasis. Their translation is a highly regulated process and is dependent on two tRNA isodecoders differing by a single 2'-O-ribose methylation called...
3.
McIntyre C, Grimont A, Park J, Meng Y, Sisso W, Seier K, et al.
Cancer Cell
. 2024 Aug;
42(9):1614-1629.e5.
PMID: 39214094
KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC...
4.
Bermejo-Rodriguez C, Araos Henriquez J, Caligiuri G, Pinto Teles S, Park Y, Evans A, et al.
Cancer Res
. 2024 Jul;
84(18):2968-2984.
PMID: 39037766
Perturbation of cell polarity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) progression. Scribble (SCRIB) is a well-characterized polarity regulator that has diverse roles in the pathogenesis of human neoplasms....
5.
Bai J, Saha S, Wood M, Chen B, Li J, Dow L, et al.
Am J Pathol
. 2024 Feb;
194(6):927-940.
PMID: 38417696
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract that are largely driven by immune cell activity, and mucosal healing is critical for remission. Serine is a...
6.
Chu K, Dow L
Cancer Res
. 2024 Feb;
84(6):798-799.
PMID: 38335538
Understanding patient-specific responses to anticancer therapies and how individual tumors interact with their tumor microenvironment (TME) is a challenging task. To measure the impact of the TME on diverse and...
7.
Torborg S, Grbovic-Huezo O, Singhal A, Holm M, Wu K, Han X, et al.
bioRxiv
. 2024 Jan;
PMID: 38234855
Control of cell identity and number is central to tissue function, yet principles governing organization of malignant cells in tumor tissues remain poorly understood. Using mathematical modeling and candidate-based analysis,...
8.
Li Z, Zhuang X, Pan C, Yan Y, Thummalapalli R, Hallin J, et al.
Cancer Discov
. 2023 Nov;
14(2):308-325.
PMID: 37931288
Significance: Treatment resistance limits response to KRAS inhibitors in LUAD patients. We find LUAD residual disease following KRAS targeting is composed of AT1-like cancer cells with the capacity to reignite...
9.
Blair L, Juan J, Sebastian L, Tran V, Nie W, Wall G, et al.
Nat Commun
. 2023 Oct;
14(1):6422.
PMID: 37828026
Tumors acquire alterations in oncogenes and tumor suppressor genes in an adaptive walk through the fitness landscape of tumorigenesis. However, the interactions between oncogenes and tumor suppressor genes that shape...
10.
Li Z, Zhuang X, Pan C, Yan Y, Thummalapalli R, Hallin J, et al.
bioRxiv
. 2023 Oct;
PMID: 37808711
Significance: Treatment resistance limits response to KRAS inhibitors in LUAD patients. We find LUAD residual disease following KRAS targeting is composed of AT1-like cancer cells with the capacity to reignite...